Views & Analysis Keeping ahead of the curve Jon Williams, President of Evidera, is well-placed to offer his views on the issues impacting access to therapies.
Views & Analysis Pharma 2022: big pharma will remain a constant Pharma 2022: big pharma to maintain its position, ready to pounce on any newcomer that shows promise.
Views & Analysis Get real: virtual reality for healthcare comes of age After a few false dawns over the years, has virtual reality’s time come?
Views & Analysis Healthcare in 2030: what role for pharma? Prevention and self-management increasingly important in healthcare systems of the future.
Views & Analysis Highs and lows in regenerative medicine How developments in gene editing and screening technology are advancing regenerative medicine.
Views & Analysis The future of brand management What pharma brand management must entail to ensure pharma retains its position and maintains sales.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.